Arich Enterprise (4173) Monthly Revenue

Market: TPEx (OTC) · Industry: Biotech & Medical · 久裕

Arich Enterprise (4173) reported revenue of NT$183 million for Oct 2026, +68.1% year on year and +2.4% from the previous month. Revenue for Jan–Oct 2026 was NT$1.42 billion (+13.5% year on year).

Revenue for Oct 2026 was a record high (previous high: Sep 2026, NT$178.7 million). →

Year-on-year revenue growth: 4 months in a row. →

In Oct 2026, it ranked No. 46 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$108.1 million24/10Nov 2024 NT$108.7 millionDec 2024 NT$124.3 millionJan 2025 NT$124.6 millionFeb 2025 NT$163.3 million25/02Mar 2025 NT$105.9 millionApr 2025 NT$105.6 millionMay 2025 NT$117.3 millionJun 2025 NT$155.8 million25/06Jul 2025 NT$115.2 millionAug 2025 NT$126.8 millionSep 2025 NT$125.7 millionOct 2025 NT$108.8 million25/10Nov 2025 NT$145.3 millionDec 2025 NT$152.7 millionJan 2026 NT$177 millionFeb 2026 NT$101.4 million26/02Mar 2026 NT$133 millionApr 2026 NT$122.7 millionMay 2026 NT$109.7 millionJun 2026 NT$143.8 million26/06Jul 2026 NT$123.7 millionAug 2026 NT$144.2 millionSep 2026 NT$178.7 millionOct 2026 NT$183 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$183 million+68.1%+2.4%
Sep 2026NT$178.7 million+42.1%+23.9%
Aug 2026NT$144.2 million+13.7%+16.6%
Jul 2026NT$123.7 million+7.3%-14.0%
Jun 2026NT$143.8 million-7.7%+31.0%
May 2026NT$109.7 million-6.4%-10.6%
Apr 2026NT$122.7 million+16.2%-7.7%
Mar 2026NT$133 million+25.6%+31.1%
Feb 2026NT$101.4 million-37.9%-42.7%
Jan 2026NT$177 million+42.0%+15.9%
Dec 2025NT$152.7 million+22.8%+5.1%
Nov 2025NT$145.3 million+33.6%+33.5%
Oct 2025NT$108.8 million+0.7%-13.4%
Sep 2025NT$125.7 million+4.6%-0.8%
Aug 2025NT$126.8 million+17.0%+10.1%
Jul 2025NT$115.2 million+16.5%-26.1%
Jun 2025NT$155.8 million+37.0%+32.8%
May 2025NT$117.3 million+5.2%+11.1%
Apr 2025NT$105.6 million+14.7%-0.3%
Mar 2025NT$105.9 million+7.2%-35.2%
Feb 2025NT$163.3 million+102.9%+31.0%
Jan 2025NT$124.6 million-6.0%+0.3%
Dec 2024NT$124.3 million+19.5%+14.3%
Nov 2024NT$108.7 million+20.7%+0.6%
Oct 2024NT$108.1 million+23.2%-10.1%

Jan–Oct 2026 cumulative: NT$1.42 billion (+13.5% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: Arich Enterprise vs PEC / Arich Enterprise vs Lotus Pharm / Arich Enterprise vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

Company remark (original Chinese)

主係流感疫情升溫致相關業績提升。

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16